Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study "AFASAK I"


Phase N/A Results

Trial Description

To compare the effects of warfarin, low-dose aspirin, or placebo on the incidence of thromboembolic complications in patients with chronic non-rheumatic atrial fibrillation.


  • Aspirin (stroke prevention) Drug
    Intervention Desc: Antiplatelet agent; inhibits thromboxane A2
  • Warfarin (Coumadin┬«)Drug
    Intervention Desc: Anticoagulant (Vitamin K antagonist)

Trial Design

Placebo-controlled, randomized trial.

Patient Involvement

Eligible patients were randomized to receive warfarin (openly), or to blindly receive either aspirin (75 mg once daily) or placebo. Follow up exams were performed at three months and six months, then every six months for two years.


Type Measure Time Frame Safety Issue
Primary Stroke, TIA, or embolic complications at two years.